News | Heart Failure | May 19, 2022

Cardionomic Announces First Patient Enrolled in STIM-ADHF Study

Study evaluates therapy optimization and system management of endovascular pulmonary neuromodulation in ADHF

Study evaluates therapy optimization and system management of endovascular pulmonary neuromodulation in ADHF

May 19, 2022 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their STIM-ADHF Study. The study will evaluate therapy optimization and system management of the Cardiac Pulmonary Nerve Stimulation (CPNS) System in patients suffering from Acute Decompensated Heart Failure (ADHF), defined as new or worsening symptoms of heart failure. The first patient was enrolled by Martin Hudec, MD., PhD., Principal Investigator at SUSCCH, Banská Bystrica, Slovakia. Up to fifty patients are expected to be enrolled worldwide.

Cardionomic's treatment is founded on the principle that autonomic nerve stimulation improves hemodynamics. The Cardionomic CPNS System is comprised of a stimulation console and an endovascular catheter that delivers targeted stimulation to the pulmonary artery. Early studies have demonstrated that the CPNS System increases cardiac contractility in chronic heart failure patients without significantly changing heart rate.

"Cardionomic continues to gain clinical experience demonstrating cardiac neuromodulation and increasing contractility have the potential to become an important treatment for ADHF patients," said Steve Goedeke, President and Chief Executive Officer of Cardionomic, Inc.

"Outcomes for patients admitted for ADHF remain poor, having not significantly improved for decades. Current therapies, such as diuretics and inotropes, are limited as they primarily focus on symptom relief," said Martin Hudec, MD., PhD., Head of the Acute Cardiology Unit at the Cardio-Center in Banská Bystrica, Slovakia. "The CPNS System provides a novel approach by stimulating the nerve branches surrounding the right pulmonary artery with the goal of improving cardiac contractility to set a new hemodynamic baseline which addresses both the root cause and the symptoms of ADHF."  

For more information: www.cardionomicinc.com


Related Content

News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
News | Heart Failure

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive ...

Home March 25, 2025
Home
News | Heart Failure

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...

Home March 21, 2025
Home
News | Heart Failure

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...

Home January 07, 2025
Home
News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 18, 2024 – Astellas Pharma Inc. recently announced that Digitiva, a non-invasive digital health solution for heart ...

Home September 19, 2024
Home
News | Heart Failure

Aug. 21, 2024 — The incidence rate of heart failure was 2- to 3-fold higher among American Indian populations than rates ...

Home August 21, 2024
Home
Subscribe Now